Has research informed us on the practical drug treatment of schizophrenia?

Schizophrenia Bulletin

Volumn 34, Issue 3, 2008, Pages 403-405

  Davis, John M ^a,b   Leucht, Stefan ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG SAFETY; EDITORIAL; EMERGENCY TREATMENT; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OPTIMAL DRUG DOSE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT OUTCOME; DELAYED RELEASE FORMULATION; ECONOMICS; EMERGENCY HEALTH SERVICE; HEALTH CARE COST; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; RESEARCH;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; EMERGENCY MEDICAL SERVICES; HEALTH CARE COSTS; HUMANS; INFORMATION DISSEMINATION; RESEARCH; SCHIZOPHRENIA; TREATMENT OUTCOME; TRUTH DISCLOSURE;

EID: 47749099983     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn011     Document Type: Editorial

References (9)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
2. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
3. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2008;8:1-19.
4. Geddes J, Freemantle N, Harrison P, Bebbington P. The National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia systematic overview and meta-regression analysis. Br Med J. 2000;321:1371-1376.
5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564.
6. Davis JM, Chen N. Dose-response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192-208.
7. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48(8):739-745.
8. Huf G, Coutinho ES, Adams CE. TREC-Rio trial: a randomised controlled trial for rapid tranquilization for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. BMC Psychiatry. 2002;2:11.
9. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-2095.